Evidence map›Paper›PMID 33827946›Full record

ArticleJournal of virology2021

Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement.

Qingbo Liu, Peng Zhang, Huiyi Miao, Yin Lin, Young Do Kwon, Peter D Kwong, Zahra Rikhtegaran-Tehrani, Michael S Seaman, Anthony L DeVico, Mohammad M Sajadi and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Qingbo LiuLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA qingbo.liu@nih.gov plusso@niaid.nih.gov.
Peng ZhangLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Huiyi MiaoLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Yin LinLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Young Do KwonVaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.ORCID 0000-0003-3560-232X
Zahra Rikhtegaran-TehraniDivision of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Anthony L DeVicoDivision of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Mohammad M SajadiDivision of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Paolo LussoLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA qingbo.liu@nih.gov plusso@niaid.nih.gov.ORCID 0000-0002-2813-4081
National Institute of Allergy and Infectious Diseases · USUniversity of Maryland, Baltimore · USBeth Israel Deaconess Medical Center · US

Funding

Neutralization Mechanisms Of Anti-HIV-1 Monoclonal AntibodiesZIAAI005022 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$24.6M
Structure-Function Studies of the HIV-1 Envelope Glycoproteins and Development of VLP-forming vaccine strategies for HIV-1ZIAAI001197 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LUSSO, PAOLO · 2014 to 2025
$16.8M
Project 3- Mucosal Determinants of Virus TransmissionP01AI124912 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI GALLO, ROBERT C · 2016 to 2019
$14.4M
Novel bNAB-based treatment and prevention of HIV-1R01AI155150 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SAJADI, MOHAMMAD MOHSENI · 2021 to 2024
$2.8M
Engineering of pan-neutralizing anti-HIV envelope antibodiesR01AI147870 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SAJADI, MOHAMMAD MOHSENI · 2020 to 2024
$2.5M
Multispecific antibodies as therapeutic agents for HIV-1I01BX004525 · VA · BALTIMORE VA MEDICAL CENTER · PI Mohammad Mohseni Sajadi · 2020 to 2027
–
BLRD VA I01 BX004525NIAID NIH HHS P01 AI124912NIAID NIH HHS R01 AI147870NIAID NIH HHS R01 AI155150
6 · The paper itself

Abstract

Broadly neutralizing antibodies (bNAbs) are the focus of increasing interest for human immunodeficiency virus type 1 (HIV-1) prevention and treatment. Although several bNAbs are already under clinical evaluation, the development of antibodies with even greater potency and breadth remains a priority. Recently, we reported a novel strategy for improving bNAbs against the CD4-binding site (CD4bs) of gp120 by engraftment of the elongated framework region 3 (FR3) from VRC03, which confers the ability to establish quaternary interactions with a second gp120 protomer. Here, we applied this strategy to a new series of anti-CD4bs bNAbs (N49 lineage) that already possess high potency and breadth. The resultant chimeric antibodies bound the HIV-1 envelope (Env) trimer with a higher affinity than their parental forms. Likewise, their neutralizing capacity against a global panel of HIV-1 Envs was also increased. The introduction of additional modifications further enhanced the neutralization potency. We also tried engrafting the elongated CDR1 of the heavy chain from bNAb 1-18, another highly potent quaternary-binding antibody, onto several VRC01-class bNAbs, but none of them was improved. These findings point to the highly selective requirements for the establishment of quaternary contact with the HIV-1 Env trimer. The improved anti-CD4bs antibodies reported here may provide a helpful complement to current antibody-based protocols for the therapy and prevention of HIV-1 infection.

Indexed as

Binding Sites, AntibodyProtein EngineeringAntibodies, MonoclonalBinding SitesBroadly Neutralizing AntibodiesCD4 AntigensEpitopesHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHumansModels, MolecularMutationProtein BindingProtein MultimerizationAntibodies, MonoclonalBroadly Neutralizing AntibodiesCD4 AntigensEpitopesgp120 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120Protein Subunitshuman immunodeficiency virusmutagenesisneutralizing antibodiespreventionprotein structure-functionrecombinant protein productionretroviral therapyviral envelope

Identifiers

PMID33827946
PMCPMC8315909
OpenAlexW3149947056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.